Pharmaceuticals

IFRS 15 Revenue – Are you good to go?

May 2017

kpmg.com/ifrs
Are you good to go?

IFRS 15 will change the way many pharma companies account for sales contracts.

To help you drive your implementation project to the finish line, we’ve pulled together a list of key considerations that many pharma companies need to focus on.
For each of the following, documenting your analysis and the conclusions drawn will be essential.
Performance obligations

Do your agreements include elements that meet the new ‘distinct’ test to be accounted for separately?

Think about...
Licence for compound combined with R&D and manufacturing services
Have you determined how to account for your licensing arrangements?

- **Is the licence distinct?**
  - Yes: Use licence guidance
  - No: Apply general guidance

- **Does the customer have a right to use the entity’s IP?**
  - Yes: Point-in-time recognition
  - No: Over-time recognition
Variable consideration

For variable payments, have you decided on the estimation method and applied the constraint?

- Expected value
- Most likely amount

Could there be a significant revenue reversal?

Think about...
Milestone payments | Volume discounts | Bonuses | Rights of return
Do your royalty arrangements qualify for the royalty exception?

- **Does the royalty relate only or predominantly to a licence for IP?**
  - Yes
  - No

- **Is it sales- or usage-based?**
  - Yes
  - No

**Exception applies – Recognise revenue as sales or usage occurs**

**Apply general guidance**

Think about …

**Tiered royalties | Royalty with a guaranteed minimum**
Do deferred or advance payment terms in your contracts give rise to a significant financing component?

- **Interest expense**
- **Interest income**
- **Advance payment**
- **Deferred payment**
- **Performance date**

**Practical expedient – No need to recognise if period between payment and performance is < 1 year**

**Does not apply if consideration is entirely variable – e.g. royalty arrangements**
Allocating the transaction price

How will you determine the **stand-alone selling prices of your performance obligations and allocate the transaction price**?

Think about …

Allocation of upfront fees | Performance obligations with variable pricing
Timing of revenue recognition

Will there be any changes to the timing of your revenue recognition?

Revenue is recognised...

At the point in time when the customer obtains control

or

Over time if specific criteria are met

Think about...
Licences | Milestones | R&D services | Contract manufacturing | Distribution

© 2017 KPMG IFRG Limited, a UK company limited by guarantee. All rights reserved.
Collaborative arrangements

Under your agreements, do you share with the customer the risks and rewards of participating in an activity or process?

Then...

Part or all of the agreement may be outside the scope of IFRS 15

Reimbursements might be recorded as a reduction of R&D expense or as other income

Think about...

Arrangements that include R&D activities or product development
Transition adjustments

Have you identified all of the areas where differences exist between IFRS 15 and your existing accounting?

Use the helpful guidance in our Transition Options and Issues In-Depth publications

IFRS 15 is more detailed than the existing revenue requirements, so you may find unexpected changes in your accounting.
Disclosure requirements

Have you identified the **additional information and processes needed** to meet the disclosure requirements?

Read our *Guide to annual financial statements – IFRS 15 supplement*

Under IFRS 15, you’ll need to provide more detailed information about contract terms, as well as how and when you recognise revenue.
# Checklist of actions

<table>
<thead>
<tr>
<th>Have you…?</th>
<th>✔</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determined whether your contracts include more than one performance obligation?</td>
<td></td>
</tr>
<tr>
<td>Determined how to account for your licensing arrangements?</td>
<td></td>
</tr>
<tr>
<td>Revised your estimates of variable consideration elements – e.g. milestone payments and volume discounts?</td>
<td></td>
</tr>
<tr>
<td>Assessed whether your royalty arrangements qualify for the royalty exception?</td>
<td></td>
</tr>
<tr>
<td>Identified and calculated any significant financing components?</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Have you…?</th>
<th>✔</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determined the stand-alone selling prices of your performance obligations and allocated the transaction price?</td>
<td></td>
</tr>
<tr>
<td>Assessed whether the timing of your revenue recognition will change?</td>
<td></td>
</tr>
<tr>
<td>Determined whether part or all of any of your agreements are collaborative arrangements?</td>
<td></td>
</tr>
<tr>
<td>Identified and quantified your transition adjustments?</td>
<td></td>
</tr>
<tr>
<td>Identified the additional information needed to meet the disclosure requirements?</td>
<td></td>
</tr>
</tbody>
</table>
How did you do?

How many of our 10 questions have you answered ‘yes’?

All 10 – You’re good to go!
6-9 – You’re on your way
0-5 – You really need to engage
Don’t forget the broader business impacts

Have you...

— updated your management reporting, including KPIs?
— developed a transition plan for parallel runs, including reconciliations?
— thought about the tax implications?
— calculated the impact on bonus schemes?
— compared your approach with peers?
Find out more

Talk to your usual KPMG contact

Use our Transition toolkit

Follow the discussion on LinkedIn

© 2017 KPMG IFRG Limited, a UK company limited by guarantee. All rights reserved.